Variables | Spirulina group (n = 36) | Placebo group (n = 37) | p |
---|---|---|---|
Age (years) | 11.67 ± 37.77 | 39.48 ± 11.03 | 0.52 a |
Sex (female/male) | 18/18 | 20/17 | 0.72c |
Height (cm) | 166.73 ± 8.38 | 165.37 ± 8.82 | 0.50 a |
Weight (kg) | 72.33 ± 13.59 | 69.72 ± 14.54 | 0.43 a |
BMI (kg/m2) | 26.01 ± 4.41 | 25.61 ± 5.05 | 0.73 a |
TAC (nmol/mL) | 281.43 ± 53.35 | 259.92 ± 61.45 | 0.11a |
MDA (nmol/mL) | 60.74 ± 16.06 | 63.30 ± 26.36 | 0.61 a |
SOD (U/mL) | 10.65 ± 4.08 | 10.21 ± 5.49 | 0.69 a |
ESR (mm/h) | 20.61 ± 19.68 | 17.56 ± 13.64 | 0.44 a |
Pentraxin 3 (ng/mL) | 13.49 ± 7.38 | 12.13 ± 8.33 | 0.37 a |
SCCAI score | 8.16 ± 2.48 | 9.02 ± 2.58 | 0.15 a |
SIBDQ score | 41.61 ± 10.95 | 42.08 ± 9.71 | 0.33 a |
Disease duration (year) | 7.16 ± 5.59 | 5.21 ± 5.02 | 0.12 a |
Dose of Mesalazine (mg/day) | 2277.77 ± 1614.41 | 1959.45 ± 1180.73 | 0.47b |
Family history n (%) | 8 (22.22) | 7 (18.91) | 0.72c |
Current medication use n (%) | Â | Â | Â |
Mesalazine (oral) | 30 (83.33) | 32 (86.48) | 0.23c |
Mesalazine (rectal) | 11 (30.55) | 12 (32.43) | 0.32c |
Sulfasalazine | 6 (16.66) | 3 (8.10) | 0.69c |
Prednisolone | 3 (8.33) | 3 (8.10) | 0.35c |
Azathioprine | 6 (16.66) | 5 (13.51) | 0.62c |